OS
Fig. 2. · Panel Fig._2
Panel Fig._2 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Masatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, Tatsuya Yamashita, Masayuki Kurosaki, Tadashi Namisaki, Shuhei Hige, Yoshito Itoh, Satoshi Mochida, Tetsuya Hosaka, Norio Akuta, Tomokazu Kawaoka, Takuya Genda, Satoshi Kobayashi, Sawako Uchida-Kobayashi, Yuting Lu, Tatsuya Ogata, Maria Jesus Jimenez Exposito, Masafumi Ikeda
Liver Cancer 15(3) 381-393
INTRODUCTION: In the preplanned interim analysis of the phase 3 CheckMate 9DW trial, first-line nivolumab plus ipilimumab demonstrated significant overall survival (OS) benefit versus lenvatinib or sorafenib (hazard ratio [HR] = 0.79; 95% confidence interval [CI]: 0.65-0.96; p = 0.018) in patients with unresectable hepatocellular carcinoma (HCC). We present outcomes in Japanese patients from this trial. METHODS: Patients with unresectable HCC without prior systemic therapy were randomized 1:1 to receive nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks (up to 4 doses, then nivolumab 480 mg every 4 weeks) or investigator's choice of lenvatinib or sorafenib. The primary endpoint was OS. Secondary endpoints included objective response rate (ORR) and duration of response (DOR) per blinded independent central review (BICR); safety was an exploratory endpoint. RESULTS: Fifty-six Japanese patients were randomized to nivolumab plus ipilimumab (n = 25) and lenvatinib or sorafenib (n = 31). After a median follow-up of 35.8 months (range: 28.2-45.3), median OS was not reached (NR) (95% CI: 16.9 months to not estimable [NE]) with nivolumab plus ipilimumab and 32.0 months (95% CI: 20.9-NE) with lenvatinib or sorafenib (HR = 0.64 [95% CI: 0.27-1.50]); 24- and 36-month OS rates were 70% versus 63% and 64% versus 40%, respectively. ORR per BICR with nivolumab plus ipilimumab was 56% (95% CI: 35-76) versus 16% (95% CI: 6-34) with lenvatinib or sorafenib. Median DOR was NR (95% CI: NE) and 11.1 months (95% CI: 6.4-NE), respectively. Grade 3/4 treatment-related adverse events occurred in 50% versus 65% of patients, respectively. There were no treatment-related deaths among Japanese patients. CONCLUSION: Consistent with the global population, first-line nivolumab plus ipilimumab showed clinically meaningful improvement in OS and ORR versus lenvatinib or sorafenib in Japanese patients with unresectable HCC, along with manageable safety. These results support nivolumab plus ipilimumab as a potential new first-line treatment for unresectable HCC in Japan.
3 个 Figure · 3 个 KM 面板
Fig. 2. Kaplan-Meier estimate of OS in all randomized Japanese patients. HR from an unstratified Cox proportional hazard model for nivolumab plus ipilimumab over lenvatinib or sorafenib. Tick marks indicate censored data. CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; OS, overall survival; SOR, sorafenib.
Fig. 2. · Panel Fig._2
Panel Fig._2 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3. Kaplan-Meier estimate of DOR in all randomized Japanese patients with a confirmed objective response. Kaplan-Meier estimate based on all patients with a confirmed complete or partial response per BICR using Response Evaluation Criteria in Solid Tumors, version 1.1 ( n = 14 in the nivolumab plus ipilimumab group; n = 5 in the lenvatinib or sorafenib group). Tick marks indicate censored data. BICR, blinded independent central review; CI, confidence interval; DOR, duration of response; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; SOR, sorafenib.
Fig. 3. · Panel DOR_in_Japanese_patients
Panel DOR_in_Japanese_patients 是同一 Fig. 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Kaplan-Meier estimate of PFS in all randomized Japanese patients. PFS assessed by BICR per Response Evaluation Criteria in Solid Tumors, version 1.1. HR from an unstratified Cox proportional hazard model for nivolumab plus ipilimumab over lenvatinib or sorafenib. Tick marks indicate censored data. BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; PFS, progression-free survival; SOR, sorafenib.
Fig. 4. · Panel KM
Panel KM 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。